NanoBio CEO to Present at the 6th Annual Grand Challenges in Global Health Meeting

Nanoemulsion-Based Intranasal Vaccine Platform Has Potential to Address a Range of Diseases in Developing Countries, Including Influenza, Hepatitis B and Respiratory Syncytial Virus

 

ANN ARBOR, Mich.--(BUSINESS WIRE)--Oct 25, 2010 - NanoBio Corporation today announced that company founder and chief executive officer James R. Baker, Jr. MD, will meet with renown scientists at the 6th Annual Grand Challenges in Global Health (GCGH) Meeting, taking place from Oct. 25-27 in Seattle, Wash., to present data illustrating the potential of the company's nanoemulsion-based needle-free intranasal vaccine platform to alleviate the suffering caused by infectious diseases in developing countries.

GCGH supports research projects that aim to achieve scientific breakthroughs needed to prevent, treat, and cure diseases of the developing world, which lacks the infrastructure to provide adequate healthcare to a population that is at risk for highly transmissible diseases. One goal of the GCGH is to improve the delivery and stability of vaccines to make them easier to transport and quicker to administer.

NanoBio recently presented Phase 1 clinical data demonstrating that the company's nanoemulsion adjuvanted intranasal flu vaccine, NB-1008, is safe, well tolerated and elicited both mucosal and systemic immune responses following a single intranasal vaccination in a study of 199 healthy adults. This first-in-man study of NanoBio's intranasal vaccine program demonstrated positive results that will serve as the basis for future clinical development plans in influenza, as well as other diseases with unmet medical needs. Dr. Baker will highlight this proof-of-concept data during his presentation at the GCGH conference and speak to the potential of nanoemulsion-based needle-free vaccines to address pandemic health concerns in developing countries.

“The unique mechanism of duel protection demonstrated by NB-1008 represents a major breakthrough for needle-free vaccines, which can positively impact populations where trained personnel are not available to administer injectable vaccines in a sterile environment,” said James R. Baker, Jr., MD, founder and chief executive officer of NanoBio. “We have shown that our technology triggers an immune response in the bloodstream and offers protection in mucosal membranes, which is where an individual is most likely to first be exposed to a virus. No marketed flu vaccine offers both systemic and mucosal protection.”

Dr. Baker's presentation will take place on Monday, October 25, 10:00-10:30 a.m.

About Grand Challenges in Global Health

The Grand Challenges in Global Health (GCGH) initiative is a major research effort to achieve scientific breakthroughs against diseases that kill millions of people each year in the world's poorest countries. The goal of the initiative is to create “deliverable technologies” – health tools that are not only effective, but also inexpensive to produce, easy to distribute, and simple to use in developing countries.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.

 

Contact: NanoBio Corporation
John Coffey, 734-302-9107
Vice President, Business Development
john.coffey@nanobio.com
or
Media Contacts:
Schwartz Communications
Stacey Holifield/Benjamin Navon
781-684-0770
nanobio@schwartz-pr.com

 

 

Posted: October 2010

View comments

Hide
(web4)